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Abstract
Background.Viral hepatitis is an infection of the liver caused by one or more of six known (HAV-HGV) hepatotropic viruses. It
is a common problem among health care workers and their patients. Surgeons are at particular risk of both acquiring and
transmitting some of these viruses from and to their patients. Unfortunately, specific immunoprophylaxis for viral hepatitis is
presently limited to protecting against the spread of hepatitis A and B viral infections, leaving a high degree of vigilance and
careful surgical technique as the only means available to prevent the transmission of other viruses relative to the surgeon. The
purpose of this paper is to review the various forms of viral hepatitis including the nature of the virus, serologic testing, clinical
features, epidemiology (with specific reference to those issues that arise in surgical practice), treatment and prevention.
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Hepatitis A
The hepatitis A virus is a 27 nanometre single-stranded
RNA virus that belongs to the Picorna family of viruses
[1]. The serologic diagnosis of an acute hepatitis A
infection is relatively straightforward. A positive IgM
antibody to hepatitis A virus (IgM anti-HAV) indicates
that infection with this virus has taken place within the
past 3–6 months [2]. Shortly after the appearance of
the IgM anti-HAV, IgG anti-HAV (often referred to as
“total” anti-HAV) appears in the circulation. Unlike
IgM anti-HAV, the IgG antibody persists for decades
and indicates long-standing immunity against future
HAV infections. Thus, individuals with acute HAV
infections are IgM anti-HAV positive and those who
are susceptible to HAV and therefore candidates for
immunoprophylaxis are IgG anti-HAV (or total anti-
HAV) negative.
The majority of acute HAV infections are subclinical
[3]. When symptoms do appear, they tend to be mild
and nonspecific in nature. Most commonly they
include fever, general malaise, fatigue, abdominal
discomfort and change in bowel habits. When severe,
dark urine, pale stool and jaundice may appear. The
severity of acute HAV infections is proportional to the
age of the patient, with younger patients tending to
have milder disease than the elderly [4]. Indeed, overall
mortality rates are only 0.1% in the general population
as opposed to 1–2% in the elderly [5]. Hepatitis A
infections do not progress to chronic liver disease (de-
fined as hepatitis persisting beyond 6 months). Rarely,
when the acute hepatitis is severe, patients may develop
cholestasis (manifest by pruritus) which can persist for
as long as 1 year following the initial injury [6].
For all intents and purposes, HAV is spread through
fecal contamination of food or drinking water [7].
Although the virus is present in blood, the limited
amount of circulating virus and short duration of
viremia render parenteral transmission of this virus
extremely uncommon. Feces of infected individuals
tend to contain the virus for a 2-week period prior to
the onset of illness and for at least 2 weeks and perhaps
as long as 3 months thereafter [8]. There are several
reports of patients in pediatric hospitals and neonatal
nurseries in particular who have transmitted HAV to
health care workers [9–12]. Nurses appear to be at
greatest risk due to their responsibility for changing
diapers [13–17]. To date, there have not been reports
of surgeons (colorectal or other) acquiring HAV from
infected patients. Similarly, there have not been re-
ports of surgeons transmitting HAV infections to their
patients.
Treatment of acute HAV infections is supportive, as
the majority of cases resolve spontaneously without
residual damage or sequelae. In those rare cases that
progress to fulminant hepatic failure, liver transplan-
tation should be considered. Both passive and active
immunoprophylaxis for HAV is available [18]. Passive
immunoprophylaxis consists of immune serum glob-
ulin (ISG) which provides prompt protection against
HAV and should therefore be administered as soon as
possible to susceptible individuals identified in hospital
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outbreaks. The half-life of ISG is relatively short and
therefore protection is limited to 3–4 months duration.
Commercially available HAV vaccines have been
developed which result in more long-term protective
antibodies (at least 5 years). Most vaccinated individ-
uals develop protective antibody levels after a single
administration of a potent formulation [19]. Although
the response to HAV vaccines is prompt, ISG is still
recommended for post-exposure prophylaxis. The
response rate to the HAV vaccine is excellent, often in
the495% range [20].
Hepatitis B
The hepatitis B virus is a 42 nanometre, double-
stranded DNA virus that belongs to the Hepadna
(Hepatitis DNA) family of viruses [21]. Although the
serology associated with this virus is often considered
complex, on most occasions, the following interpreta-
tions are valid (Table I) [22]. The presence of hepatitis
B surface antigen (HBsAg) in the blood indicates the
presence of an HBV infection. On the other hand,
antibody to HBsAg (anti-HBs) indicates immunity to
HBV infection. The antibody to the hepatitis B core
antigen (anti-HBc) indicates that the individual has
been exposed to the intact hepatitis B virus at some
time in their life. IgM anti-HBc indicates that the
exposure took place within the past 3–6 months. The
presence of early antigen (HBeAg) or antibody to
HBeAg (anti-HBe) reflects viral replicative activity
such that HBeAg positive patients have active viral
replication (all body fluids should be considered
potentially infectious), whereas HBeAg negative but
anti-HBe positive patients usually have inactive viral
replication (generally, only the patient’s blood is con-
sidered infectious to others). Unfortunately, there are
sufficient exceptions to the latter interpretation (in
particular a mutation to the pre-core gene that re-
sults in the absence of serum HBeAg despite active
viral replication and viremia) that all body fluids from
an HBsAg positive individual regardless of their
HBeAg/anti-HBe status, should be considered infec-
tious [23]. Quantitative HBV-DNA testing (which
tends to parallel HBeAg results) is a more accurate
marker of viral load and infectivity.
The natural history of HBV infections in adults can
be described in terms of three phases—acute hepatitis,
chronic hepatitis and an “inactive disease” state—with
the majority of adult patients only experiencing the first
phase. By definition, the acute hepatitis phase repre-
sents the first 6 months of the infection. During this
phase, patients are often asymptomatic or have
nonspecific complaints similar to those described with
mild HAV infections [24,25]. HBsAg, IgM anti-HBc
and HBeAg testing are frequently positive during this
phase of the illness. In 90–95% of adults the acute
hepatitis resolves spontaneously and patients develop
natural immunity (seroconvert from HBsAg to anti-
HBs positive). The more severe the acute hepatitis,
the more likely this is to occur [24]. Unfortunately,
only 5–10% of infants follow that course. Children
and adolescents have an intermediate likelihood of
spontaneously resolving their infection. If the HBsAg
remains positive for 6 months after the onset of the
illness or is documented to be positive on two occasions
6 months apart or is positive on one occasion but in the
absence of an IgM anti-HBc then the individual almost
certainly has a chronic HBV infection.
The second phase of the illness is referred to as the
chronic hepatitis phase. During this phase, which often
lasts 7–10 years in North American/European adults,
the disease is active with originally symptomatic
patients continuing to have symptoms (albeit less
severe) and liver enzyme abnormalities tending to be
abnormal in a hepatocellular injury pattern (serum
ALT levels disproportionately elevated compared with
serum alkaline phosphatase levels). The HBeAg is
often positive indicating active viral replication. Even-
tually, symptoms resolve, liver enzymes return to
normal or near-normal values and the patient sero-
converts from HBeAg to anti-HBe positive, indicating
entry into the third and final phase of the infection, the
“inactive disease” state.
The inactive disease state tends to last from years to
decades before the HBsAg spontaneously seroconverts
from positive to negative and anti-HBs appears mark-
ing resolution of the infection. During this phase,
patients are largely asymptomatic, have normal or
near-normal liver enzyme levels, are HBeAg negative
but anti-HBe positive, have low or undetectable levels
of HBV-DNA in the blood and if biopsied, have little
evidence of active inflammation.
The major complications of the hepatitis B carrier
state—cirrhosis and hepatocellular carcinoma—tend
to occur in approximately 30% and 15% of cases
respectively [26,27]. When cirrhosis does develop,
it is often present at the end of the chronic hepatitis
phase, whereas hepatocellular carcinoma tends to be
diagnosed during the late chronic hepatitis or inactive
disease phase of the infection.
Table I. Markers of hepatitis B infection and immunity
Marker Indicates
HBsAg (surface antigen) Hepatitis B infection
Anti-HBs Exposure to HBsAg in
the past, immunity
to HBV infection
HBcAg (core antigen)* Presence of replicating viral
particles in hepatocytes
IgM anti-HBc Exposure to the intact
virus within 6 months
Anti-HBc Exposure to the intact virus
at some time in life
HBeAg (early antigen) Active viral replication
Anti-HBe Nonreplicating virus
HBV-DNA4105 copies/ml Active viral replication
*Limited to testing in the liver, not serum.
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Because the majority of acute HBV infections
resolve spontaneously and viral replication is already
limited in those with inactive disease, treatment is con-
fined to the chronic hepatitis phase of HBV infections.
The only licensed treatments presently available are
interferon, lamivudine and adefovir. Response rates to
these agents in terms of converting an actively repli-
cating virus (HBeAg positive) to a nonreplicating state
(HBeAg negative and anti-HBe positive) are approxi-
mately 30–40%, but lower in those who acquired their
infections earlier in life [28–30]. Response rates are
highest in patients with low baseline levels of viral
replication and those with biochemical or histologic
evidence of active hepatic inflammation [30].
Although maternal–infant transmission is the most
common route of HBV infections in the world at the
present time, in industrialized nations, parenteral drug
abuse and needle stick exposures represent significant
high-risk activities [31]. Needle stick exposures involv-
ing blood from an individual with high levels of viral
replication (HBeAg positive or high HBV-DNA levels)
tend to result in HBV infections occurring in approxi-
mately 60% of cases, whereas when the infection in the
source is not actively replicating (HBeAg negative or
low HBV-DNA levels), the figure falls to approximately
30% [32]. In addition to the size of the inoculum,
features of the needle itself, hollow or solid, appear to
be important factors influencing the risk of viral
transmission [33,34].
The prevalence of HBV infection among health care
workers is 3–5-fold higher than that of the general
population with surgeons (particularly orthopedic
surgeons and gynecologists) and dentists having the
highest reported rates [35,36]. The annual rate of
HBV infections occurring in health care workers ranges
between 0.5 and 5% compared with an annual rate of
0.1% in the general population [37]. The risk of trans-
mission from patients to health care workers is related
to several factors including the degree of exposure to
patient blood or body fluids, blood-contaminated
sharps and the duration of employment [38]. Thus,
those at highest risk of infection are surgeons and
surgical house officers, laboratory technicians, blood
bank workers, assistants in surgery, pathologists, and
anesthetists. An additional risk factor for health care
workers is the underlying prevalence of HBV in the
patient population with higher risks in urban hospitals
and tertiary care centers than those in rural and
primary care hospitals [39].
Over the past 25 years, there have been approxi-
mately 50 reports of HBV transmission from health
care workers to patients in the United States and
Europe and 400 worldwide [40]. A large majority of
these cases involved either surgeons or dentists. The
number of patients infected by the health care worker
ranged from 1 to 55. Although HBV transmission from
dentists to patients have decreased in recent years, the
frequency of transmission from surgeons to patients
remains unaltered [40]. Between 1984 and 1993, 10
clusters associated with HBV-infected surgeons were
documented in England with a rate of transmission
to patients of 0.3–9% [41]. In several investigations,
the two major risks of transmission identified were the
presence of HBeAg and/or high levels of HBV-DNA
in the health care worker and the degree of invasive-
ness of the procedure performed (dental extraction4
dental prophylaxis, hysterectomy4curettage4cardio-
thoracic surgery4other surgery) [42]. Other minor
factors included: glove failure, skin lesions, long dur-
ation of the operation and the use of blood products.
While in the majority of cases there were no identifiable
causes for the surgical outbreaks, the most likely
explanations were thought to be related to needle sticks
incurred while suturing and inadvertent cuts through
gloves while securing knots [43]. For these reasons the
following are thought to decrease the risk of intra-
operative transmission: use of double latex gloves,
changed hourly, enclosed hood and face-masks and
operative isolator with umbilical-cord aspirator, knee-
length impermeable gowns, a combination of shoe-
covers with coverage to the knee and disposable drapes.
Inadvertent pricks or cuts should be bled and washed
immediately with iodine, soap and water. The injured
person should then be considered for immunopro-
phylaxis [44].
Both passive and active immunity against HBV are
available. The former consists of high titer anti-HBs
referred to as hepatitis B immunoglobulin (HBIG). As
with ISG for HAV, HBIG for HBV provides prompt
protection and should be given as soon as possible to
susceptible individuals following viral exposure. Gen-
erally, when the exposure was of a nonparenteral form
(sexual contact, maternal–infant, etc.) HBIG is con-
sidered effective for a period of approximately 2 weeks
post-exposure [45]. On the other hand, when the
exposure was parenteral (needle stick injury or shared
drugs) HBIG efficacy is limited to only 1 week post-
exposure [45]. The duration of protection provided by
HBIG is approximately 3–4 months.
Active immunity against HBV (the HBV vaccine)
can be acquired through a series of three vaccinations
with recombinant HBV vaccines. Approximately one-
third of individuals respond to the first dose of the
vaccine (time 0), two-thirds following dose no. 2 at
1 month and 95% following dose no. 3 at 6 months
[46]. Males and individuals over the age of 40 tend to
respond less well to the vaccine than females and
younger individuals [47]. For maximum effect, the
HBV vaccine should be administered intramuscularly.
As a result, injections in the deltoid rather than hip
(where inadvertent injection into adipose tissue is more
likely to occur) are suggested. Individuals at high risk of
HBV exposure such as health care workers should have
their response to the vaccine documented by testing
for anti-HBs approximately 2–4 weeks after the final
vaccination innoculation. Antibody levels450 IU and
perhaps410 IU should be considered protective and
indicative of long-term protection despite weakening
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or loss of antibody titers over time. This long-term
protection in the absence of appreciable antibody titres
relates to the amnestic response of vaccine responders
to subsequent viral exposures [48]. Thus, booster doses
of the vaccine at 5 years or thereafter are not presently
advocated. Nonresponders to a complete series of HBV
vaccinations should be reassessed to ensure that they
are not carriers of the virus (HBsAg positive) and if
negative, revaccinated with a second series of either
recombinant or the original plasma-derived vaccine (if
available). The response rate to a second vaccination
series is approximately 10–20% [49].
Given the safety and efficacy of the vaccine, all
healthy care workers, as well as other high risk individ-
uals, are strongly encouraged to undergo vaccination.
It is in the best interest of the health care worker
exposed to HBV to present immediately for assessment
so that appropriate post-exposure prophylaxis can be
administered if needed (see Table II). If not previously
measured, anti-HBs titers should be determined, even
in those having received a full course of HBV vaccine.
Individuals who have developed anti-HBs (and anti-
HBc) as a result of natural infections or anti-HBs as a
result of immunization in the past can be assumed to be
immune and require no further treatment. Individuals
who have never been immunized, those in whom a
response to the vaccine has not been documented or
those who have been documented to be nonresponders
should receive HBIG as soon as possible and again 1
month later. The former group (never immunized)
should be offered the first of the vaccination series at
the same time but at a different injection site. The
remainder of the vaccination series should proceed
accordingly. For those in whom an anti-HBs response
was not documented following previous vaccination,
approximately 6 months after the second HBIG admin-
istration (when passively administered anti-HBs has
cleared), the individual should receive a single injection
of HBV vaccine. If the anti-HBs titre is high (450 IU)
1–2 weeks thereafter, it can be assumed that the indi-
vidual had responded to the previous vaccine series and
no further vaccination is required. If the anti-HBs is
undetectable or only present in low titer (510 IU) the
full course of the vaccination should be completed.
Antiviral therapy for health care workers who sero-
convert from HBsAg negative to positive as a result of a
recent exposure should be withheld until the individual
has been documented to be HBsAg positive on two
occasions a minimum of 6 months apart (i.e. demon-
strated chronicity). Thereafter, considerations regard-
ing treatment such as indications, contraindications,
choice of antiviral agents, duration of therapy, etc. are
similar to those for other chronic HBV carriers [50].
Antiviral therapy may also be of value in keeping serum
HBV-DNA levels low or undetectable as a means of
limiting the risk of transmission from health care
workers to others [51].
Finally, concerns regarding documentation of the
health care worker’s HBV status and their suscepti-
bility to HBV infection can be alleviated somewhat
by anti-HBc testing in that a positive anti-HBc result
indicates that the individual has already been exposed
to the hepatitis B virus (whether a carrier or immune
can subsequently be determined by their family
physician) and would not benefit from either passive or
active immunization.
Hepatitis C
The hepatitis C virus is a 60 nanometre, single-stranded
RNA virus [52]. The diagnosis of HCV infection is
most often based on a positive anti-HCV in a patient
with a history of viral exposure (previous blood trans-
fusions or intravenous drug use) and elevated liver
enzyme tests. Many of the problems initially associated
with anti-HCV testing have since been resolved.
Specifically, third generation testing (which incorpo-
rates a wider spectrum of viral antigens in the assay) has
largely eliminated the high frequency of false-positive
results, particularly in patients with autoimmune
disorders and hypergammaglobulinemia [53]. More-
over, the delay in the appearance of anti-HCV with
acute infections (12–16 weeks) can now be circum-
vented by testing for HCV-RNA, which is often
present within 2 weeks of infection [54]. HCV-RNA
testing also helps to distinguish the small number of
patients (520%) who resolve their acute HCV infec-
tions and normalize their liver enzyme abnormalities
but remain anti-HCV positive. Finally, third and fourth
generation anti-HCV and HCV-RNA testing can be
used to establish the diagnosis in immunocompro-
mised individuals who do not develop or develop only
limited anti-HCV responses [54].
Unlike HBV infections, HCV has a high (60–80%)
propensity to progress to chronic liver disease [55,56].
As with HAV and HBV, the majority of infections
are subclinical and when symptoms do appear they
tend to be relatively nonspecific [56]. Fulminant
hepatitis appears to be uncommon in North American
forms of the disease [57]. The percentage of patients
Table II. Post-exposure prophylaxis for hepatitis B
Status HBV vaccine HBIG
Vaccinated; Not required Not required
adequate titers
of anti-HBs
documented
in the past
Vaccinated; Booster, recheck One dose
adequate titers of
anti-HBs not
previously
documented
in 1 month
Unimmunized Full course
(day 0, 1 and
6 months)
Two doses;
day 0 and 1 month
post exposure
Based on: CDC recommendations of the Immunization Practical
Advisory Committee: Post operative prophylaxis of HBV. Ann Intern
Med 1984;101:351–4.
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progressing to cirrhosis and/or hepatocellular carci-
noma remains to be determined. Retrospective follow-
up of patients thought to be infected 20–30 years
earlier suggests that 20–30% of HCV infections will
progress to cirrhosis during that time period [56].
These findings have led some investigators to suggest
that the risk of cirrhosis increases by 10% per decade.
Similarly, the risk of hepatocellular carcinoma remains
to be determined but appears to be as high as in
patients with hepatitis B infections [58]. To date,
hepatocellular carcinoma developing in HCV-infected
patients without cirrhosis is considered to be extremely
rare [59].
Until the early 1990s blood transfusions represented
the major source of HCV infections in the developed
world [60]. Following initiation of donor screening,
parenteral drug abuse has emerged as the most
common source of HCV infections [61]. The rates of
transmission through other activities such as sexual
promiscuity, homosexual contact, tattoos, ear and
body piercing, etc., appear to be relatively uncommon
but may serve as surrogate markers of higher risk
activities [61,62]. Maternal–infant transmission of
HCV occurs in approximately 5% of births, but more
often (10–15%) when the mother is immunocompro-
mised or in the acute stage of the infection (initial
6 months) at the time of delivery [63]. Between 10%
and 40% of patients have no identifiable risk factor
on careful, physician to patient interviews [61,64,65].
The risk of health care workers acquiring HCV
infections from their patients has not been defined but
appears to be relatively low. Seroepidemiologic surveys
of hospital staff have revealed anti-HCV prevalence
rates similar to those of the general population (1–
1.4%) [66]. The prevalence of HCV infections among
patients is variable and site-dependent [67–69]. The
average risk of HCV infection occurring after needle
stick injury involving HCV-infected blood has ranged
between approximately 2.5% and 10%, which is
significantly lower than the rates associated with HBV
exposure but approximately 10-fold greater than that
associated with HIV exposures (0.3%) [66,70]. Thus,
it appears that health care workers have a significantly
lower occupational risk of acquiring HCV infections
when compared with HBV infections but higher than
that for HIV infections.
When nosocomial transmission of HCV does occur,
it is often from health care workers to patients and
involves patients undergoing surgical procedures
[71,72]. Factors that appear to facilitate transmission
include needle stick injuries, inapparent glove per-
forations related to securing sutures and perhaps active
liver disease in the source with high levels of viremia
[72,73]. Interventions that are thought to limit the
risk of transmission include: selection of less invasive
surgical approaches (e.g. laparoscopic procedures),
alternatives to needles and sharps (e.g. tapes, glues,
staples), sharps with injury-preventive features (e.g.
blunted suture needles), instruments rather than hands
for retraction, avoiding the simultaneous presence of
hands from two or more surgeons in the operative field
and using a neutral zone for passing sharps rather than
from hand to hand [74].
Presently, recombinant or pegylated interferon alone
or in combination with ribavirin is the only approved
therapy for chronic hepatitis C infections. In unse-
lected cases, approximately 55% of patients will
respond to 6–12 months of therapy with normalization
of liver enzyme abnormalities and loss of HCV-RNA
[75–78]. With selection of patients (those infected with
genotypes 2 or 3, low viral load, early disease and lim-
ited hepatic inflammation) long-term response rates to
interferon treatment are improved [79].
Passive and active immunoprophylaxis against HCV
have yet to be developed, leaving standard infection
control measures, a high degree of vigilance, proper
surgical techniques, and screening of blood donors as
the only effective means of limiting the spread of this
virus in the hospital setting [80]. When such efforts fail
and a clear exposure to HCV-contaminated blood or
fluids has occurred, the individual should be screened
for underlying HCV infection (baseline anti-HCV) and
tested for HCV-RNA by PCR at 1, 3 and 6 months
thereafter. If HCV-RNA is detected and remains pos-
itive for three months, antiviral therapy with standard
recombinant or perhaps, pegylated interferon plus
ribavirin (trials presently underway) for 4–6 months
should be undertaken unless contraindications to one
or both of these agents exist [81,82].
Hepatitis D
The hepatitis D agent is a single-stranded RNA viroid
(incomplete virus) which requires the replicative
capacity of HBV to infect and replicate in humans [83].
Thus, only patients simultaneously co-infected with
HBV and HDV or those with pre-existing chronic
HBV infections who are subsequently exposed to HDV
can acquire HDV infections. The disease is most often
diagnosed by the presence of high titered antibodies to
HDV (anti-HDV) in a patient with serologic evidence
of HBV infection (HBsAg or IgM anti-HBc positive)
[84]. Often, the HDV patient has a particularly severe
form of hepatitis which more rapidly progresses to
cirrhosis yet has little evidence of active HBV replica-
tion (HBeAg negative). HDV also appears to be
responsible for 2–20% of previously considered
fulminant hepatitis B infections [85].
HDV infections are most often spread via parenteral
transmission [86]. Sexual or intimate contact and
maternal–infant transmission are less common and
largely confined to certain areas of the world [87].
There are no reported cases in the English literature
of HDV transmission occurring from patients to health
care workers or vice versa.
Treatment for HDV infection is as outlined for HBV
infections in that eradication of the latter will result in
clearance of the former.
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While passive and active immunoprophylaxis against
HBV in HBV-susceptible individuals will also protect
against HDV infection, there is no effective HDV
immunoprophylaxis for the established HBV carrier
who remains at risk of acquiring HDV infection.
Hepatitis E
The hepatitis E virus is a single-stranded RNA virus
belonging to the Calici virus family [88]. A positive
anti-HEV test is used to establish the diagnosis [89].
Like HAV, HEV does not cause chronic liver disease
and is spread by fecal/oral transmission [90–92]. Un-
like HAV and other hepatatropic viruses, the mortality
of acute HEV infections in pregnant women is high
(15–20%) [93]. The reason(s) for this finding has yet to
be determined.
Regarding nosocomial transmission, there is a single
case report of a pregnant woman returning from India
to South Africa with fulminant hepatitis where the
HEV was subsequently transmitted to a nurse (con-
firmed serologically) and presumed to have also been
transmitted to an additional nurse and physician (not
serologically confirmed). The mode of transmission in
this case (or cases) was thought to have been related
to the staff members having assisted the patient from a
bedpan and/or having transferred her to the operating
room for repair of vaginal lacerations [94]. There have
been no case reports of health care workers transmit-
ting HEV to their patients.
Because acute HEV infections resolve spontaneously
and do not progress to chronic hepatitis, antiviral ther-
apy is less urgent. However, patients with fulminant
hepatic failure secondary to HEV infections should be
considered for liver transplantation.
Passive and active immunoprophylaxis have yet to be
developed for HEV infections.
Hepatitis G
Recently, a new RNA virus (and closely related
variants) was discovered by independent groups of
investigators [95–97]. This agent is referred to as the
hepatitis G virus or HGV. One of the groups respon-
sible for its discovery employed sera from a surgeon
(initials GB) who had developed jaundice (attributed
to non-A, non-B hepatitis but was subsequently tested
and found to be negative for HCV-RNA) as the es-
sential reagent in their assay. Although there is some
homology between HGV and HCV it is not sufficient
to warrant considering HGV a new HCV genotype.
Presently, the diagnosis of HGV infection is estab-
lished by documenting the presence of HGV-RNA in
the serum [98].
Little is known of the natural history of HGV
infections [99]. Data suggest that infection with this
virus is associated with but not responsible for as many
as 20% of previously undiagnosed fulminant, acute
and chronic hepatitis as well as “cryptogenic cirrhosis”
cases [100]. Concerns regarding nosocomial trans-
mission of HGV have largely been limited to the
dialysis setting [101–103]. However, postoperative
HGV infection has also been described [104]. Fortu-
nately, such cases are infrequently associated with
biochemical evidence of hepatitis.
The high prevalence of this virus in the general
population (estimated to be approximately 1--2%) sug-
gests that the route of transmission may extend beyond
blood transfusions and intravenous drug usage to
include sexual and perhaps maternal–infant and other
forms of nonparenteral transmission [105]. The risk of
transmission from patients to health care workers and
vice versa beyond the setting of hemodialysis units
remains to be determined.
Conclusion
Hepatitis viruses can be transmitted from patients to
health care workers and vice versa. While the majority
of these infections involve HBV and HCV, other
hepatotropic viruses as well as viruses that are non-
hepatropic such as HIV (for which effective post-
exposure prophylaxis is available) should also be
considered. Needle stick injuries and suturing are
the most common routes of transmission within the
hospital setting. Environmentally mediated infections
of hepatotropic viruses (such as blood contamination
of countertops and equipment dials or switches, etc.)
are rare, with only HBV having a sufficient viral load
in the blood and resistance to physical insults to render
it a risk for such forms of transmission. Although
therapeutic and preventive measures have improved
significantly in recent years, viral hepatitis remains a
common and dangerous infection to surgeons. Until
new, more effective interventions are developed, a
greater awareness of the viruses, the diseases they cause
and how to minimize the risks of their transmission
remain the best defense for health care workers, other
high-risk groups and patients.
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